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Abstract 
Background: Individuals with diabetes have remarkably high rates of cardiovascular morbidity and mortality. How‑
ever, the incremental cardiovascular risk in diabetes is heterogeneous and has often been related to renal involve‑
ment. The purpose of this study was to analyse the prognostic value of subclinical atherosclerosis in determining the 
incidence of first cardiovascular events (CVEs) in individuals with diabetes and chronic kidney disease (CKD) compared 
to CKD individuals without diabetes.
Methods: We included data from individuals with CKD with and without diabetes, free from pre‑existing cardiovas‑
cular disease, from the NEFRONA cohort. Participants underwent baseline carotid and femoral ultrasound and were 
followed up for 4 years. All CVEs during follow‑up were registered. Bivariate analysis and Fine–Gray competing risk 
models were used to perform the statistical analysis.
Results: During the mean follow‑up time of 48 months, a total of 203 CVE was registered. 107 CVE occurred among 
participants without diabetes (19.58 per 1000 person‑years) and 96 CVE occurred among participants with diabetes 
(44.44 per 1000 person‑years). Following the competing risk analysis, the variables predicting CVEs in CKD individu‑
als without diabetes were the number of territories with plaque at baseline (HR 1.862, 95% CI [1.432;2.240]), age (HR 
1.026, 95% CI [1.003;1.049]) and serum concentrations of 25‑OH vitamin D (HR 0.963, 95% CI [0.933;0.094]). The only 
variable predicting CVEs among CKD participants with diabetes was the number of territories with plaque at baseline 
(HR 1.782, 95% CI [1.393, 2.278]). For both models, concordance (C) index yielded was over 0.7.
Conclusions: The burden of subclinical atherosclerosis is the strongest predictor of future CVEs in diabetic individuals 
with CKD. Early detection of subclinical atherosclerotic burden by multiterritorial vascular ultrasound could improve 
CVE prediction in this population.
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Background
It is well established that individuals with diabetes have 
an increased risk of developing cardiovascular disease 
(CVD) as well as poorer cardiovascular outcomes com-
pared to the general population [1]. For the last two 
decades, diabetes has been considered an equivalent 
condition to CVD [2], and this heightened cardiovascu-
lar risk has been emphasized in former clinical guide-
lines [3, 4]. That said, some studies have reported that 
although individuals with diabetes show a two to fourfold 
increased risk of CVD, this risk is not equivalent to that 
of individuals who have had a cardiovascular event (CVE) 
[5–8]. These data support the concept of heterogene-
ity in cardiovascular risk within the diabetic population 
and therefore underline the need for cardiovascular risk 
stratification [9, 10].
On the other hand, quantification of the burden of 
atherosclerotic plaque assessed by noninvasive ultra-
sonography is a strong predictor for CVEs and, hence, 
is considered a valid tool for cardiovascular risk stratifi-
cation [11, 12]. In addition, several studies support the 
value of measuring subclinical atherosclerosis (SA) in 
multiple arterial territories for an improved CVE pre-
dictive value and, thus, a more accurate cardiovascular 
risk stratification [13, 14]. In addition, the substantial 
impact of declining renal function and albuminuria on 
cardiovascular risk has been broadly acknowledged in the 
literature [15]. In fact, it has been reported that in indi-
viduals with diabetes, the presence of chronic kidney dis-
ease (CKD) is associated with an increased risk of CVD, 
explaining in part their heightened burden of CVD [16].
To date, there is limited evidence describing the spe-
cific prevalence of SA in individuals with both diabetes 
and CKD. Recently, our group reported that SA is more 
prevalent, carries a higher plaque burden and is more 
rapidly progressive in individuals with CKD and diabe-
tes [17]. In addition, our group also reported that renal 
individuals show a higher prevalence of plaques [18, 19] 
and a higher incidence of future CVEs across all stages of 
CKD compared with controls [20].
Therefore, we examined the prognostic value of mul-
titerritorial vascular evaluation and the extent of SA in 
predicting the incidence of new CVEs in individuals with 
renal disease and diabetes, using data from the National 
Observatory of Atherosclerosis in Nephrology (NEF-
RONA) study [21]. We hypothesized that the additional 
atherosclerotic plaque burden that involves having both 
conditions would be a marker of an increased risk of 
CVEs and contribute to the prediction of the incidence 
of CVEs among CKD individuals with diabetes in our 
cohort.
Thus, the aim of our study was to analyse the incidence 
of CVEs and its association with baseline subclinical 




The present study included 1747 individuals with CKD 
without diabetes and 698 individuals with CKD with dia-
betes from the NEFRONA cohort. The design, objective 
and methods of the NEFRONA study have been pub-
lished in detail previously [21]. Briefly, the NEFRONA 
study is a multicentre, prospective observational study. 
We aimed to evaluate the prevalence and evolution of 
subclinical atheromatosis in CKD individuals, as well as 
the contribution of vascular imaging for a more precise 
cardiovascular risk assessment.
Between October 2010 and June 2012, 2445 CKD indi-
viduals with and without diabetes who were free from 
previous cardiovascular disease and were 18 to 75 years 
of age were recruited from 81 Spanish hospitals and 
dialysis clinics [19]. Participants with known CVD or 
who had undergone any carotid artery intervention were 
excluded. Other exclusion criteria were pregnancy, life 
expectancy of less than 12 months, any active infection or 
previous organ transplantation. Participants underwent 
baseline carotid and femoral ultrasound examinations. 
During a 4-year follow-up period, all cardiovascular 
events, noncardiovascular deaths and kidney transplan-
tations were registered.
The Ethical Committees of all involved Spanish neph-
rology centres approved this study with the final approval 
by the Ethics committee board of the Hospital Universi-
tario Arnau de Vilanova (Lleida, Spain). The investigation 
has been conducted according to the principles expressed 
in the Declaration of Helsinki, and all the included par-
ticipants provided written informed consents.
Clinical data and laboratory examinations
Information on the participant’s medical history, cardio-
vascular risk factors and drug use was collected at base-
line. Dyslipidaemia was therefore defined as a recorded 
clinical diagnosis or current use of lipid-lowering medi-
cation. A detailed history was taken. A physical examina-
tion including standard vital tests and anthropometric 
measures, such as height, weight and waist–hip ratio, 
was performed [21]. A routine fasting blood test was 
carried out within 3  months of the vascular ultrasound 
examination, and biochemical parameters were obtained. 
The estimated glomerular filtration rate was determined 
using the Modification of Diet in Renal Disease Study 
formula (MDRD-4). High-sensitive C reactive protein 
(hsCRP) plasma concentrations were measured with an 
immunoturbidimetric method (Roche/Hitachi modu-
lar analytics). Serum concentrations of 25-OH vitamin 
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D were determined by an ELISA (IDS, UK) as described 
previously [20].
Diagnosis of diabetes mellitus
The criteria used to make the diagnosis of diabetes and, 
thus, to include a individual in the diabetes group have 
been reported previously [17]. The criteria used were 
as follows: a previous diagnosis of diabetes recorded in 
the individual’s medical history, a fasting plasma glu-
cose ≥ 126 mg/dl or HbA1c ≥ 6.5% determined by labora-
tory testing or a current prescription of any anti-diabetic 
drug.
Carotid and femoral imaging
B-mode ultrasound and colour Doppler examinations 
of carotid and femoral sites were performed using the 
Vivid BT09 apparatus (GE Healthcare, Waukesha, WI) 
equipped with a 6–13 MHz broadband linear array probe 
previously explained [21]. The presence of atheromatous 
plaque was assessed in ten vascular territories: internal, 
bulb and common carotid, and common and superfi-
cial femoral arteries. Atheromatous plaque was defined 
as intima media thickness (cIMT) > 1.5  mm protruding 
into the lumen, according to the ASE Consensus State-
ment [22] and the Mannheim cIMT Consensus [23]. The 
ultrasound examination was performed in a blinded fash-
ion by three itinerant teams belonging to the UDETMA 
(Unit for Detection and Treatment of Atherothrom-
botic Diseases, Hospital Universitari Arnau de Vilanova, 
Lleida, Spain) using semi-automatic EchoPAC Dimension 
software (GE Healthcare) according to a standardized 
protocol. To evaluate intraobserver plaque assessment 
reliability, a sample of 20 randomly chosen subjects was 
assessed 3 to 5 times on different days, obtaining a kappa 
coefficient of 1 and, therefore, indicating excellent intrao-
bserver reliability [20].
Follow‑up period and cardiovascular events
Participants were followed-up for 4  years. During the 
follow-up period, data on fatal and nonfatal cardiovas-
cular events were recorded by the referring physician as 
reported previously [20]. The CVE were defined accord-
ing to the International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD9-CM], which 
includes unstable angina, myocardial infarction, tran-
sient ischaemic attack, cerebrovascular accident, conges-
tive heart failure, arrhythmia, peripheral arterial disease 
or amputation due to peripheral arterial disease, and 
aortic aneurism [21]. Cardiovascular mortality causes 
included myocardial infarction, arrhythmia, congestive 
heart failure, stroke, abdominal aortic aneurism, mesen-
teric infarction, and sudden death. CVEs and death were 
accurately recorded. Noncardiovascular death and kid-
ney transplants were also recorded during follow-up.
Statistical analysis
Data for quantitative variables are presented as a median 
and interquartile range, and qualitative variables are pre-
sented as a number and percentage. Participant char-
acteristics were compared between nondiabetic and 
diabetic participants using the Mann–Whitney U test 
and Pearson’s Chi-square test for non-normal quantita-
tive and categorical variables, respectively.
The association between potential risk factors and 
CVEs was investigated using bivariate analyses (Cox pro-
portional hazards model). Significant variables in bivari-
ate analyses and potential confounding factors were used 
to develop appropriate multiple models for estimating 
CVE risk under competitive risk conditions.
The Fine–Gray competing risk regression model was 
used to estimate the contribution of baseline patient 
characteristics to the cumulative incidence of CVEs. 
Noncardiovascular death and kidney transplantation 
were both considered competing events. Different mod-
els were fitted for CKD participants without diabetes as 
well as for CKD participants with diabetes. The model in 
each case was selected using the Bayesian information 
criteria [24]. A concordance index (C-index) was used to 
measure the discriminative power of the Fine–Gray mod-
els at 24 and 48  months. A statistical significance level 
of 0.05 was used. The statistical analysis was carried out 
with R statistical software version 3.3.1.
Results
Baseline patient characteristics and study endpoints
The participants included 1747 CKD individuals with-
out diabetes and 698 CKD individuals with diabetes. The 
baseline characteristics of the participants are described 
in Table 1. The median follow-up time was 48 months in 
both groups.
During the mean follow-up time of 48 months, a total 
of 203 CVE was registered, of which 107 occurred among 
participants without diabetes and 96 among participants 
with diabetes. Corresponding CVE rates were 19.58 ver-
sus 44.44 per 1000 person-years, respectively (Additional 
file 1: Figure S1). We also observed that among diabetes 
participants, CVE rates increased with declining renal 
function: CVE rates were 30.90 per 1000 person-years 
in CKD-3 versus 41.14 per 1000 person-years in CKD-
4/5 and 100.67 per 1000 person-years in individuals on 
renal replacement therapy (RRT) (p-trend < 0.001). This 
tendency was milder among renal participants with-
out diabetes: CVE rates were 15.04 per 1000 person-
years in CKD-3 versus 18.19 per 1000 person-years in 
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CKD-4/5 versus 31.72 per 1000 person-years for RRT 
(p-trend < 0.001). (Additional file 1: Figure S1).
Among women without diabetes, the CVE rate during 
follow-up was 16.04 per 1000 person-years and in men 
without diabetes, it was 22.05 per 1000 person-years. 
Among women with diabetes, the CVE rate was 32.17 per 
1000 person-years, whereas among men with diabetes, it 
was 50.92 per 1000 person-years. Women with diabetes 
presented with more CVEs than men without diabetes 
(32.17 versus 22.05 per 1000 person-years, respectively; 
p = 0.0019), and this was observed consistently across 
all stages of CKD. In line with this result, stage 3 CKD 
women with diabetes experienced a slightly higher rate 
of incident CVEs compared to men with diabetes and 
stage 3 CKD (31.52 versus 30.67 per 1000 person-years, 
respectively) (Additional file 1: Figure S1).
Factors associated with CVE
Among CKD participants without diabetes, the bivariate 
analysis showed that age (HR 1.04, 95% CI [1.02;1.06]), 
Table 1 Population baseline characteristics
CKD chronic kidney disease, RRT renal replacement therapy, eGFR estimated glomerular filtration rate determined by the Modification of Diet in Renal Disease Study 






Gender, male 1047 (59.9%) 461 (66.0%) 0.006
CKD stage < 0.001
 CKD‑3 662 (37.9%) 288 (41.3%)
 CKD‑4/5 551 (31.5%) 256 (36.7%)
 RTT 534 (30.6%) 154 (22.1%)
Age [years] 59.0 [48.0;67.0] 65.0 [56.0;70.0] < 0.001
Current smoker 967 (55.4%) 404 (57.9%) 0.275
Hypertension 1554 (89.0%) 673 (96.4%) < 0.001
25‑OH vitamin D [ng/ml] 15.4 [11.4;19.6] 13.8 [10.4;18.5] < 0.001
eGFR [ml/min per 1.73  m2] 31.6 [20.9;44.3] 31.7 [21.5;44.2] 0.812
Glucose [mg/dl] 92.0 [85.0;101] 133 [108;164] < 0.001
Total cholesterol [mg/dl] 177 [153;205] 171 [143;197] < 0.001
HDL cholesterol [mg/dl] 48.0 [39.0;59.0] 44.0 [36.0;53.9] < 0.001
LDL cholesterol [mg/dl] 103 [82.0;123] 92.0 [71.4;113] < 0.001
non‑HDL cholesterol [mg/dl] 128 [105;153] 122 [100;148] 0.011
Triglycerides [mg/dl] 118 [89.0;162] 147 [103;205] < 0.001
hsCRP [mg/dl] 1.86 [0.90;4.17] 2.58 [1.16;5.84] < 0.001
Antidiabetic treatment < 0.001
 Diet – 166 (23.8%)
 Oral hypoglycemic drugs – 164 (23.5%)
 Insulin treatment – 368 (52.7%)
HbA1c [g/dl] 5.40 [5.10;5.70] 6.80 [6.10;7.80] < 0.001
Albumin/creatinine ratio mg/g 89.1 [11.2;384] 149 [18.6;601] 0.001
Pulse pressure [mmHg] 56.0 [47.0;69.0] 68.0 [54.0;81.0] < 0.001
Antihypertensive treatment 1506 (86.2%) 650 (93.1%) < 0.001
Lipid‑lowering drugs 975 (55.8%) 465 (66.6%) < 0.001
Number of plaques 1.00 [0.00;3.00] 3.00 [1.00;5.00] < 0.001
Presence of any plaque 1138 (65.1%) 570 (81.7%) < 0.001
Presence of carotid plaques 901 (51.6%) 502 (71.9%) < 0.001
Carotid plaque [only] 291 (16.7%) 165 (23.6%) < 0.001
Presence of femoral plaques 847 (48.5%) 405 (58.0%) < 0.001
Femoral plaque [only] 237 (13.6%) 68 (9.74%) 0.012
> 2 territories with plaque 853 (48.8%) 465 (66.6%) < 0.001
Carotid and femoral plaques 610 (34.9%) 337 (48.3%) < 0.001
Follow‑up time [months] 48.4 [27.1;52.0] 48.3 [25.7;52.0] 0.675
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RRT (HR 2.23, 95% CI [1.40;3.55]), current smoker (HR 
1.60, 95% CI [1.08;2.39]), serum concentration of HDL-
cholesterol (0.98, 95% CI [0.96;0.99]), serum concentra-
tion of hsCRP (HR 1.01, 95% CI [1.00;1.03]) and pulse 
pressure values (1.02, 95% CI [1.01;1.03]) were associ-
ated with the occurrence of CVEs during the follow-up 
period (Additional file 1: Table S1). Among CKD partici-
pants with diabetes, factors associated with a CVE were 
RRT (HR 3.58, 95% CI [2.16;5.93]) and insulin treatment 
(HR 1.87, 95% CI [1.06;3.30]). Additionally, in this group 
of CKD participants with diabetes, being a female was 
associated with fewer CVEs (0.63, 95% CI [0.40;1.00]) 
as well as having better renal function (HR 0.98, 95% CI 
[0.96;1.00]) (Additional file 1: Table S1). In both groups, 
it was found that serum concentrations of 25-OH vita-
min D were inversely associated with the incidence of 
CVE, participants without diabetes HR 0.96, 95% CI 
[0.93;0.99], and participants with diabetes HR 0.95, 95% 
CI [0.92;0.98] (Additional file 1: Table S1).
In both the nondiabetic and diabetic study groups, the 
bivariate analysis showed that the presence of plaque (HR 
5.83, 95% CI [2.95;11.54] and HR 3.39, 95% CI [1.48;7.75], 
respectively) and the number of territories with basal 
plaque (HR 1.26, 95% CI [1.18;1.35] and HR 1.18, 95% CI 
[1.09;1.27], respectively) as well as having more than two 
vascular territories affected with plaque at baseline (HR 
3.26, 95% CI [2.09;5.07] and HR 3.35, 95% CI [1.87;6.01], 
respectively) were associated with suffering from a CVE 
during follow-up (Table 2). To the same extent, the pres-
ence of atherosclerotic plaques in both vascular sites, 
carotid and femoral, was also found to be positively asso-
ciated with incident CVEs in both groups (HR 2.57, 95% 
CI [1.75;3.78] and HR 2.09, 95% CI [1.37;3.17], respec-
tively) (Table 2).
Following the competing risk model analysis, the vari-
ables predicting CVE in CKD participants without diabe-
tes were the number of territories with plaque at baseline 
(HR 1.862, 95% CI [1.432;2.240]), age (HR 1.026, 95% CI 
[1.003;1.049]) and serum concentrations of 25-OH vita-
min D (HR 0.963, 95% CI [0.933;0.094]) (Table  3). On 
the other hand, among CKD participants with diabetes, 
the only variable that predicted CVEs was the number 
Table 2 Bivariate unadjusted analysis of the plaque at baseline according to the incidence of cardiovascular events
CVE fatal and non-fatal cardiovascular event
*p values correspond to HR. Chi-squared test for trend in proportions p < 0.005
CKD without diabetes CKD with diabetes
No CVE N = 1640 CVE N = 107 HR [95% CI] p value* No CVE N = 602 CVE N = 96 HR [95% CI] p value*
Territories with plaque 1.0 [0.0;3.0] 3.0 [2.0;5.0] 1.26 [1.18;1.35] < 0.001 2.0 [1.0;5.0] 4.0 [2.0;6.0] 1.18 [1.09;1.27] < 0.001
Presence of plaque 1040 (63.4%) 98 (91.6%) 5.83 [2.95;11.54] < 0.001 480 (79.7%) 90 (93.8%) 3.39 [1.48;7.75] 0.004
Presence of carotid 
plaque
815 (49.7%) 86 (80.4%) 3.80 [2.36;6.12] < 0.001 418 (69.4%) 84 (87.5%) 2.86 [1.56;5.24] 0.001
Carotid plaque [only] 267 (16.3%) 24 (22.4%) 1.41 [0.90;2.22] 0.137 143 (23.8%) 22 (22.9%) 0.92 [0.57;1.49] 0.748
Presence of femoral 
plaque
773 (47.1%) 74 (69.2%) 2.42 [1.60;3.64] < 0.001 337 (56.0%) 68 (70.8%) 1.81 [1.17;2.82] 0.008
Femoral plaque [only] 225 (13.7%) 12 (11.2%) 0.83 [0.45;1.51] 0.538 62 (10.3%) 6 (6.25%) 0.56 [0.25;1.29] 0.173
> 2 territories with plaque 772 (47.1%) 81 (75.7%) 3.26 [2.09;5.07] < 0.001 382 (63.5%) 83 (86.5%) 3.35 [1.87;6.01] < 0.001
Carotid and femoral 
plaque
548 (33.4%) 62 (57.9%) 2.57 [1.75;3.78] < 0.001 275 (45.7%) 62 (64.6%) 2.09 [1.37;3.17] 0.001
Table 3 Fine and Gray multiple regression to model incidence of cardiovascular events
The variables introduced to build the model were: gender, age in years, smoking, CKD stage, HDL cholesterol, 25-OH vitamin D and the square root of number of 
territories with plaque(s) at baseline, and glycated haemoglobin, oral treatment, and insulin treatment only for DM patients
CKD chronic kidney disease, Baseline PL [sq] the square root of number of territories with plaque
CKD without diabetes CKD with diabetes
HR [95% CI] p‑value HR [95% CI] p‑value
Age 1.026 [1.003;1.049] 0.024 – –
Baseline PL [sq] 1.862 [1.432;2.420] < 0.001 1.782 [1.393;2.278] < 0.001
25‑OH vitamin D 0.963 [0.933;0.994] < 0.001 – –
C‑index (24 months) 78.88 71.82
C‑index (48 months) 75.63 71.49
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of territories with plaque at baseline (HR 1.782, 95% CI 
[1.393;2.278]) (Table  3). Estimated C-index values over 
0.7 were found for the selected model in each group 
(Table 3).
Discussion
In the present study, we found that in CKD participants 
with diabetes and without known CVD, an increased 
burden of basal atherosclerotic plaque translates into an 
increased risk of incident CVEs. We also demonstrated 
that the number of vascular territories affected with 
plaque is the strongest associated factor for future CVEs 
in CKD individuals with diabetes, whereas in nondiabetic 
CKD individuals, other factors influenced the occurrence 
of CVE, such as age and serum concentrations of 25-OH 
vitamin D. To the best of our knowledge, this is an origi-
nal work showing that in individuals with CKD and dia-
betes, multiterritorial vascular ultrasonography could 
help in future CVE prediction.
Atherosclerosis burden and CVE
Atherosclerosis is a diffuse condition. Historically, nec-
ropsy examinations have revealed extensive atheroscle-
rotic lesions in subjects experiencing fatal CVEs [25], 
thus linking CVD and atherosclerosis burden. Data from 
the literature have shown that the detection of preclinical 
atherosclerosis improved cardiovascular risk prediction 
beyond traditional cardiovascular risk factors [26, 27]. In 
addition, the quantification of plaque burden improved 
risk prediction even further [27–29]. Proxy measures 
of atherosclerosis burden, including noninvasive tech-
niques, such as coronary artery calcification (CAC) score 
and vascular ultrasonography, have been the object of 
multiple investigations as a tool to predict incident CVEs. 
In individuals without established CVD, previous stud-
ies have reported that atherosclerosis burden, meas-
ured either by CAC score or plaque burden at carotid 
or femoral sites, is a strong and independent predictor 
of CVEs [30, 31]. A high atherosclerotic burden has also 
been associated with increased cardiovascular and total 
mortality risk [32–34], even in very elderly people [35]. 
Additionally, data from prior studies including renal par-
ticipant cohorts have also demonstrated the relationship 
between atherosclerosis burden and CVD. A study from 
our group published in 2017 [20] found that the number 
of arterial territories affected with atherosclerotic plaque 
predicted the occurrence of CVEs in a cohort of asymp-
tomatic renal individuals, including all-stages of CKD. 
Likewise, in a work that followed 226 individuals on hae-
modialysis for 5 years with carotid ultrasonography [36], 
plaque number was found to be an independent marker 
of fatal CVEs.
Concerning individuals with diabetes, the atheroscle-
rotic burden measured by the CAC score has been shown 
to predict CVEs in asymptomatic subjects [7], while the 
presence of carotid and/or lower limb atherosclerosis 
assessed by ultrasonography has been shown to be asso-
ciated with the prevalence of CVD [37], with the risk 
being greater in those subjects with concomitant carotid 
and femoral atherosclerosis.
Other factors associated with CVE
The analysis of associated factors with the incidence of 
CVEs in our cohort of individuals has shown that age and 
serum 25-OH vitamin D concentrations were predictive 
of CVEs only in CKD individuals without diabetes, while 
the number of territories with plaque at baseline was 
predictive of CVEs both in individuals with and without 
diabetes.
Age is a well-known factor for CVD [38]. In our study, 
age was independently associated with CVEs in CKD 
individuals without diabetes but not in those with diabe-
tes, inferring that individuals with diabetes present with 
a higher incidence of CVEs at younger ages, as has been 
reported in the literature [39]. Likewise, the association 
between 25-OH vitamin D serum concentrations and the 
incidence of CVE found in the present study in individu-
als without diabetes is in keeping with studies that appear 
to link vitamin D deficiency to CVD [40].
In the current analysis, there were no other risk factors 
that improved the assessment of CVE risk once added to 
the number of territories with plaque. Strikingly, the only 
factor predicting CVEs in this group with diabetes was 
atherosclerotic burden.
In fact, in our study, sex was not a risk factor for the 
incidence of CVEs in individuals with or without diabe-
tes. In the general population, it is known that nondia-
betic women have fewer CVEs than nondiabetic men of 
the same age. However, this advantage appears to be lost 
in the presence of diabetes [41–45]. The present study is 
in agreement with these findings showing that the loss of 
the protective cardiovascular sex effect is also observed 
in women with diabetes and CKD. This statement is rein-
forced by the fact that the incidence of CVEs in women 
from our cohort with diabetes was higher than that in 
men without diabetes, as well as by the data that the inci-
dence of CVEs was similar in women with diabetes in 
stage 3 CKD compared to males with diabetes with simi-
lar kidney function.
Regarding cardiovascular risk prediction in patients 
with diabetes, Colom et al. have recently described that 
in patients with type 1 diabetes without previous cardio-
vascular disease alterations in the composition of HDL 
are associated with subclinical coronary artery disease 
as well as with an increased volume of epicardial adipose 
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tissue suggesting that HDL composition may be a link 
between coronary atherosclerosis and the accumulation 
of this type of adipose tissue in these subjects [46]. Also 
in subjects with type 1 diabetes free from CV disease, our 
group has recently described that presence of advanced 
stages of diabetic retinopathy are associated with pres-
ence and burden of subclinical carotid atherosclerosis 
[47]. On the other hand, in healthy normotensive and 
normoglycaemic subjects classical risk factors, such as 
age and blood pressure, have been found to be associated 
with subclinical vascular damage while no association 
has been found with plasma biomarkers involved in the 
inflammatory process of atherosclerosis [48].
Finally, as we have demonstrated in the present work, 
quantification of atherosclerotic lesions by vascular ultra-
sonography is a feasible and reliable tool for CVE predic-
tion. It should also be noted that new three-dimensional 
[28] and contrast-enhanced ultrasonography [49] could 
improve vascular assessment even further and thus con-
tribute to refining the early prediction of CVEs.
Limitations
A limitation of the current work relates to the baseline 
clinical characteristics relevant to diabetes that were not 
available due to the inherent nature of the NEFRONA 
study that was initially designed to investigate renal dis-
ease and cardiovascular risk. In addition, the endpoints 
registered during the observation period entailed the 
discontinuation of the follow-up after a first CVE, after 
nonCV death or after renal transplantation. However, 
this has been considered and mitigated with the compet-
ing risk analysis.
Conclusions
CVD screening in asymptomatic individuals with dia-
betes remains controversial [50]. Moreover, CVD risk 
stratification remains an important challenge in the CKD 
population. However, our results shed some light on this 
matter. We have demonstrated that multiterritorial ultra-
sonography is a valid and strong noninvasive tool to help 
predict CVEs among diabetic individuals with CKD. In 
this subgroup of high-risk individuals, quantifying SA by 
the combined application of carotid and lower extremity 
vascular ultrasonography could improve CVE prediction 
and may help identify those individuals with higher CV 
risk. The strategies implemented in routine practice to 
efficiently quantify subclinical arterial lesions in diabetic 
individuals with CKD might be of clinical benefit and 
should be considered with a special emphasis on younger 
women with diabetes.
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